{"filing":{"accession_number":"0001213900-26-072907","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ea0296232-6k_neurosense.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026072907/ea0296232-6k_neurosense.htm"},"events":[{"id":14533,"run_id":12944,"accession_number":"0001213900-26-072907","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This is a press release announcing positive Phase 2b clinical trial results for NeuroSense's lead drug candidate PrimeC in ALS. The disclosure reports achievement of the primary efficacy endpoint (statistically significant TDP-43 reduction, p=0.0421), previously reported clinical outcomes including slowing of disease progression and survival benefit, and advancement toward Phase 3 trials. While not a financial earnings release in the traditional sense, this is a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and prospects. The language (\"achieved primary endpoint,\" \"statistically significant,\" \"compelling body of evidence\") and the detailed clinical data presentation mirror the structure and materiality of an earnings-type announcement for a clinical-stage biotech company.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":[{"id":12004,"accession_number":"0001213900-26-072907","item_number":"EX-99.1","item_title":"ea029623201ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a press release announcing positive Phase 2b clinical trial results for NeuroSense's lead drug candidate PrimeC in ALS. The disclosure reports achievement of the primary efficacy endpoint (statistically significant TDP-43 reduction, p=0.0421), previously reported clinical outcomes including slowing of disease progression and survival benefit, and advancement toward Phase 3 trials. While not a financial earnings release in the traditional sense, this is a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and prospects. The language (\"achieved primary endpoint,\" \"statistically significant,\" \"compelling body of evidence\") and the detailed clinical data presentation mirror the structure and materiality of an earnings-type announcement for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:30:38.874383+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12004,"accession_number":"0001213900-26-072907","item_number":"EX-99.1","item_title":"ea029623201ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a press release announcing positive Phase 2b clinical trial results for NeuroSense's lead drug candidate PrimeC in ALS. The disclosure reports achievement of the primary efficacy endpoint (statistically significant TDP-43 reduction, p=0.0421), previously reported clinical outcomes including slowing of disease progression and survival benefit, and advancement toward Phase 3 trials. While not a financial earnings release in the traditional sense, this is a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and prospects. The language (\"achieved primary endpoint,\" \"statistically significant,\" \"compelling body of evidence\") and the detailed clinical data presentation mirror the structure and materiality of an earnings-type announcement for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T13:30:38.874383+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-06-29"}]}